PlainPharmaWatch

CMS Open Payments · Program Year 2024

Leadiant Biosciences, Inc.

Leadiant Biosciences, Inc. reported $1,341,626.35 across General Payments, Research, and Ownership to 65 physicians and teaching hospitals across 71 transactions.

See the rankings → How this is sourced
$1.3M
All-tracks total
71
Transactions
65
Recipients
−$12.3K
General Payments vs PY2023

Leadiant Biosciences, Inc. reported $1,341,626.35 across all CMS Open Payments tracks (General + Research + Ownership) to 65 physicians and teaching hospitals in Program Year 2024 - ranking #550 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $6,682.35, averaging $20.6K per recipient.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the publisher.

CMS Sunshine Act warrant

Manufacturer leadiant-biosciences-inc Leadiant Biosciences, Inc.

$1.3M · #550/1,925 · 0.0% industry · PY2024

  • TOT $1.3M
  • RANK #550
  • SHARE 0.0%
  • TXN 71
  • RCP 65
  • CAT 2
  • GEN $6.7K
  • ΔGEN −$12.3K
  • TOP1 37.4%
  • PY 2024

Volume peers

Nearest volume peer: Surmodics, Inc. ($1.3M)

Biofrontera Bioscience GmbH$1.3MVericel Corporation$1.3MTelix Pharmaceuticals$1.3MLeadiant Biosciences, Inc. (…$1.3MSurmodics, Inc.$1.3M
All-tracks payment totals near Leadiant Biosciences, Inc. (CMS Open Payments PY2024)

Leadiant Biosciences, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

Release-over-release change

General Payments changed from PY2023 to PY2024

Leadiant Biosciences, Inc.'s CMS-reported General Payments decreased by $12.3K (−64.8%) from PY2023 to PY2024.

How this year-over-year comparison is scoped

The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.

CMS source labels for this exact identifier: PY2022: LEADIANT BIOSCIENCES, INC.PY2023: LEADIANT BIOSCIENCES, INC.PY2024: Leadiant Biosciences, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$19.0KPY2024$6.7K
PY2023
$18,990.08
PY2024
$6,682.35

What the Data Shows for Leadiant Biosciences, Inc.

Leadiant Biosciences, Inc. ranks #550 out of 1,925 companies in the CMS Open Payments database for Program Year 2024, a comparatively small 0.0% slice of all industry payments reported nationwide for the year. The underlying total is $1,341,626.35 across 71 transactions to 65 physicians and teaching hospitals - $18.9K per transaction and $20.6K per recipient on average.

Of the 2 general-payment categories charted below, "Consulting Fee" is the largest at $5.0K across 2 transactions, 74.8% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).

General Payment Breakdown by Type

Leadiant Biosciences, Inc. made 2 types of general payments. "Consulting Fee" is the largest category at $5.0K, 74.8% of General Payments.

How Leadiant Biosciences, Inc. divides its payments

How the reported total splits across payment categories

1. Consulting Fee$5.0K2. Food and Beverage$1.7K
Payment Type Amount Transactions
Consulting Fee $5.0K 2
Food and Beverage $1.7K 63

Recipient Concentration in General Payments

The five largest recipient relationships account for $5,235.11 (78.3%) of $6,682.35 in this company's General Payments records across 58 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Leadiant Biosciences, Inc.

The five named recipients with the highest reported General Payments from this company

Aaron Miller$2.5KMonte Del Monte$2.5KFrancis Rossignol$99.71Mark Eggleston$77.64Kimathi Blackwood$57.76
  1. 1

    Aaron Miller

    $2,500.00 across 1 reported transactions

  2. 2

    Monte Del Monte

    $2,500.00 across 1 reported transactions

  3. 3

    Francis Rossignol

    $99.71 across 1 reported transactions

  4. 4

    Mark Eggleston

    $77.64 across 2 reported transactions

  5. 5

    Kimathi Blackwood

    $57.76 across 2 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as Leadiant Biosciences, Inc.'s, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Leadiant Biosciences, Inc..

Promega Corporation

HHI 2814

Analog Devices Inc.

HHI 2816

SRS Medical Systems, Inc.

HHI 2811

Wardlow Enterprises

HHI 2803

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with Leadiant Biosciences, Inc..

Showing 6 of 1,924 companies with CMS-reported payment data.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download Leadiant Biosciences, Inc.'s data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.